Compare Natera Inc. Common Stock (NTRA) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Real Estate Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Vanguard Real Estate Index Fund ETF trades at $90.08 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| NTRA | VNQ | |
|---|---|---|
Market Cap | $57.03B | $70.80B |
Volume | 1,131,157 | 3,568,223 |
Sector | Health | — |
52-Week High | $425.64 | $100.95 |
52-Week Low | $179.42 | $87.00 |
Typical Hold Time | 0 Days | 113 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VNQ, the Vanguard Real Estate ETF, trades at $91.14, down 0.24% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Recent news highlights pressure from rising Treasury yields and Fed rate hikes, contributing to a nearly 10% decline over the past month. The ETF's dividend yield is now competitive with T-bills, but sector headwinds persist due to interest rate sensitivity.
Outlook remains cautious amid interest rate uncertainty, with potential long-term value for contrarian investors. Risks include further rate hikes eroding income appeal, while opportunities lie in historically attractive entry points for well-capitalized REITs. Investors should weigh yield sustainability against macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
